FGFR1 and breast carcinoma: Most importantly, in a patient-derived xenograft model with FGFR1-amplified ER+ breast cancer, the addition of the selective FGFR TKI erdafitinib to palbociclib and fulvestrant led to a complete tumor regression in some of the animals.